Trial Profile
Phase I trial of an interleukin-1 receptor-associated kinase 4 inhibitor as a potential therapy for cancer.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 07 May 2015
Price :
$35
*
At a glance
- Drugs Interleukin-1 receptor-associated kinase inhibitors (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 07 May 2015 New trial record